Given that CD56 serves as a key diagnostic marker for identifying neuroendocrine-derived cells (including SCLC) in immunohistochemistry, its specific expression on the cell surface also renders it a potential therapeutic target for treating this aggressive cancer. This evidence concerns the gene NCAM1 and small cell lung carcinoma.